Board of Directors
Marc Rubin, MD
Dr. Rubin has served as Titan's Executive Chairman of the Board of Directors since 2009, after previously holding the position of CEO. Prior to joining Titan, Dr. Rubin was Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Before Bayer Pharmaceuticals and Schering AG merged in June 2006, Dr. Rubin was a member of the Board of Executive Directors of Schering AG, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. Previously, Dr. Rubin held the position of Senior Vice President of Global Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline. At GlaxoSmithKline, Dr. Rubin was responsible for programs in United States, Europe, Asia and Latin America. Prior to joining GlaxoSmithKline, he served on the Senior Staff of the Infectious Diseases Section of the National Cancer Institute, NIH. Dr. Rubin was trained in Internal Medicine at The Johns Hopkins Hospital, and held fellowships in both Oncology and Infectious Diseases at the NIH. Dr. Rubin holds an M.D. from Cornell University Medical College, and has board certification in Internal Medicine, Oncology, and Infectious Diseases. He currently serves on the board of directors of Curis Inc. and Galectin Therapeutics, as well as several private companies and an academic institution.
Sunil Bhonsle, MBA
President and CEO
Sunil Bhonsle has served as Titan's President since 2009, after previously holding the positions of Executive Vice President and Chief Operating Officer. Prior to joining Titan, Mr. Bhonsle served for 20 years at Bayer Corp., where he was Vice President and General Manager-Plasma Supply in the Biological Products business unit. Over the years Mr. Bhonsle has held positions of increasing responsibility in the areas of Finance and Operations in the Biological Products business unit, including serving as a member of the Executive Management Committee, at a time when Bayer became a leading supplier of plasma products worldwide. Mr. Bhonsle holds an M.B.A. from the University of California at Berkeley and a B.Tech. in chemical engineering from the Indian Institute of Technology.
Joseph A. Akers
Mr. Akers has served as president of Bayer's hematology/cardiology business, where he oversaw the core of Bayer's specialty pharmaceuticals development, with significant products in hematology and specialty cardiology. Mr. Akers also served as president and CEO of Bayer Business and Corporate Services and held numerous other financial and executive positions during his 37-year career with the company. He has served on the boards of Haemacure Corp., POINT Biomedical Corp. and Schein Pharmaceuticals.
Eurelio M. Cavalier
Compensation Committee; Corporate Governance and Nominating Committee
Mr. Cavalier has been a Director of Titan Pharmaceuticals since September 1998. Mr. Cavalier served as Group Vice President of the U.S. Pharmaceuticals Business Unit of Eli Lilly & Company until his retirement in 1994.
M. David MacFarlane, PhD
Audit Committee; Corporate Governance and Nominating Committee
Dr. MacFarlane has been a Director of Titan Pharmaceuticals since May 2002. Dr. MacFarlane served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. Prior to joining Genentech, Inc., he served in various positions with Glaxo, Inc., last as Vice President of Regulatory Affairs.
James R. McNab, Jr.
Corporate Governance and Nominating Committee
Mr. McNab, an entrepreneur experienced in building and growing companies, is co-founder and chairman of Curis, a publicly traded oncology company that partnered with Roche to develop and commercialize a first-in-class hedgehog inhibitor for the treatment of advanced basal cell carcinoma. Mr. McNab serves as CEO and chairman of Palmetto Pharmaceuticals, executive chairman of FirstString Research Inc., and chairman of JT Pharmaceuticals. Previously Mr. McNab was founder of Vidus Ocular, a glaucoma device company that was sold to OPKO Health, and co-founder of Sontra Medical, which developed a medical low frequency ultrasound device from Massachusetts Institute of Technology that was sold to Echo Therapeutics.
In his current role as president of global inflammation and immunology, Mr. Smith leads a team of over 1,300 people and is responsible for the inflammation and immunology portfolio, including all global commercial, clinical development, regulatory, medical affairs and finance activities. Prior to joining Celgene, Mr. Smith was vice president, general manager and head of strategic and business analysis at Biovail Pharmaceuticals Inc., where he managed commercial business units in the U.S. and Canada. He also worked for nearly a decade at Pharmacia & Upjohn and the Upjohn Company in the U.S., Hong Kong and Europe. Mr. Smith has extensive experience in product development and commercialization as well as business development. He holds a BSc in chemistry and an HBSc degree in pharmacology and toxicology from the University of Western Ontario and a Master's of International Business Management from the American Graduate School of International Management (Thunderbird).
Rajinder Kumar, MD
Dr. Kumar is the founder, chairman and CEO of MeRaD Pharmaceutical in Cambridge, England, a company focused on the development of novel anti-infective products for treating drug-resistant bacterial infections. Previously, Dr. Kumar held senior positions in big pharma, biotech and academia. Prior to founding MeRaD, he served in various executive capacities with Dr. Reddy's Labs, Ranbaxy Laboratories Limited, Synaptic Pharmaceutical LLP, Glaxo SmithKline, and SmithKline Beecham. Over the years he has successfully launched several new products and has clinical, regulatory, and commercial experience in the U.S., European Union, Japan and other Asian countries. Dr. Kumar has also served on scientific advisory boards in the fields of neuroscience, anti-infectives and metabolic disorders. He received a B.S. in Human Biology from the University of London, a Master's in Ethology from the University of Birmingham, a Bachelor of Medicine and Bachelor of Surgery from the University of Dundee and an advanced diploma in Psychological Medicine from The Royal College of Surgeons and Physicians in Ireland.